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Abstract 
Sunitinib (Sutent®) is a receptor tyrosine kinase (RTK) and angiogenesis inhibitor approved for the 
treatment of renal cell carcinomas, gastrointestinal stromal tumours and pancreatic neuroendocrine 
tumours. A key structural motif retained throughout medicinal chemistry efforts during sunitinib's 
development was the indoline-2-one group. In the search for new anti-angiogenic scaffolds, we previously 
reported that non-indoline-2-one-based derivatives of semaxanib (SU5416, a structurally simpler sunitinib 
predecessor that underwent Phase III trials) are active as angiogenesis inhibitors, indicating that the 
group is not essential for activity. This Letter describes the synthesis and structure-activity relationships 
of another class of non-indoline-2-one angiogenesis inhibitors related to sunitinib/semaxanib; the 
5,7-dimethyl-2-aryl-3H-pyrrolizin-3-ones. A focussed library of 19 analogues was prepared using a simple 
novel process, wherein commercially available substituted arylacetic acids activated with an amide 
coupling reagent (HBTU) were reacted with the potassium salt of 3,5-dimethyl-1H-pyrrole-2-carbaldehyde 
in one-pot. Screening of the library using a cell-based endothelial tube formation assay identified 6 
compounds with anti-angiogenesis activity. Two of the compounds were advanced to the more 
physiologically relevant rat aortic ring assay, where they showed similar inhibitory effects to semaxanib at 
10 μg/mL, confirming that 5,7-dimethyl-2-aryl-3H-pyrrolizin-3-ones represent a new class of angiogenesis 
inhibitors. 
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Abstract 
Sunitinib (Sutent®) is a receptor tyrosine kinase (RTK) and angiogenesis inhibitor approved for the 
treatment of renal cell carcinomas, gastrointestinal stromal tumours and pancreatic neuroendocrine 
tumours. A key structural motif retained throughout medicinal chemistry efforts during sunitinib’s 
development was the indoline-2-one group. In the search for new anti-angiogenic scaffolds, we 
previously reported that non-indoline-2-one-based derivatives of semaxanib (SU5416, a structurally 
simpler sunitinib predecessor that underwent Phase III trials) are active as angiogenesis inhibitors, 
indicating that the group is not essential for activity. This report describes the synthesis and structure-
activity relationships of another class of non-indoline-2-one angiogenesis inhibitors related to 
sunitinib/semaxanib; the 5,7-dimethyl-2-aryl-3H-pyrrolizin-3-ones. A focussed library of 19 analogues 
was prepared using a simple novel process, wherein commercially available substituted arylacetic acids 
activated with an amide coupling reagent (HBTU) were reacted with the potassium salt of 3,5-
dimethyl-1H-pyrrole-2-carbaldehyde in one-pot. Screening of the library using a cell-based endothelial 
tube formation assay identified 6 compounds with anti-angiogenesis activity. Two of the compounds 
were advanced to the more physiologically relevant rat aortic ring assay, where they showed similar 
inhibitory effects to semaxanib at 10 g/mL, confirming that 5,7-dimethyl-2-aryl-3H-pyrrolizin-3-ones 
represent a new class of angiogenesis inhibitors. 
   
Sunitinib 1 (Sutent®, Pfizer, Figure 1)1 is an indolin-2-one-based angiogenesis inhibitor 
approved for the treatment of vascularised renal cell carcinomas,2 gastrointestinal stromal tumours3 and 
pancreatic neuroendocrine tumours.4 Its mechanism of action involves inhibition of at least eight 
different receptor tyrosine kinases (RTKs), including vascular endothelial growth factor receptors 1-3 
(VEGFR1-VEGFR3), platelet-derived growth factor receptors (PDGFR)  and , stem cell factor 
receptor (Kit), Fms-like tyrosine kinase 3  (FLT-3) and colony-stimulating factor-1 receptor (CSF-1R).5 
The indolin-2-one (oxindole) portion was considered crucial for activity of sunitinib 1 and was retained 
throughout development. Indeed, the structurally simpler indolin-2-one predecessor semaxanib 
(SU5416) 2 underwent a Phase III clinical trial for advanced colorectal cancer.6 In recent work, we 
showed that in spite of its perceived importance the indolin-2-one moiety is not essential for anti-
angiogenic activity in this class, demonstrating that ring-opened 3,5-dimethyl-1H-pyrrol-2-yl-2-
arylacrylate 3 variants of semaxanib 2 inhibit angiogenesis in a rat aortic ring model.7 We now report 
the discovery of a second class of non-indolin-2-one-based angiogenesis inhibitors related to sunitinib 
1/semaxanib 2; the 5,7-dimethyl-2-aryl-3H-pyrrolizin-3-ones 4 (Figure 1). 
 
Figure 1. Angiogenesis inhibitors related to sunitinib 1. 
 
 We hypothesised that 5,7-dimethyl-2-aryl-3H-pyrrolizin-3-ones might possess anti-angiogenic 
properties due to their structural similarity to sunitinib 1, SU5416 2 and acrylates 3.  The hypothesis 
was tested by developing  new chemistry to create a small library of analogues carrying systematic 
variations at the 2-aryl ring and investigating their structure-activity relationships (SAR). Sporadic 
reports of 3H-pyrrolizin-3-ones have appeared in the literature but little remains known about their 
chemistry and biological activity.8-13 Complex structures incorporating a 3H-pyrrolizin-3-one-type core 
have been reported, including tricyclic pyrrolo-indolones, pyrrolo-isoindolones, tetracyclic isoindolo-
indolones and other polycyclic heterocycles.14-15 A number of these are marine natural products or their 
derivatives.16 
 
 Divergent access to 5,7-dimethyl-2-aryl-3H-pyrrolizin-3-ones appeared achievable in one-pot 
from 3,5-dimethyl-1H-pyrrole-2-carbaldehyde 5 and the many commercially available substituted 
phenylacetic acids. We had previously shown that the K+ salt of 5 (generated using KH in THF) is 
smoothly N-acylated by methyl chloroformate,7  leading us to consider that the same salt might also 
undergo N-acylation reactions with phenylacetic acids pre-activated as acid halides or with amide 
coupling reagents. A simple, divergent synthesis was envisaged wherein activated phenylacetic acids 
generated in one flask are combined with the K+ salt of 5, which had been freshly prepared in a 
separate flask. Mixing of the flasks would initiate pyrrole N-acylation/amide formation and ensuing 
benzylic proton abstraction under the basic reaction conditions (excess KH) would trigger an 
intramolecular Knoevenagel condensation to deliver 5,7-dimethyl-2-aryl-3H-pyrrolizin-3-ones. 
 
 Preliminary synthetic efforts surveying a variety of amide coupling reagents, procedures and 
rates and orders of addition in model reactions with phenylacetic acid and pyrrole aldehyde 5 yielded 
5,7-dimethyl-2-phenyl-3H-pyrrolizin-3-one 6 as the major product in many instances, as observed by 
TLC analysis. The highest yield of 6 (48%, Scheme 1) was obtained when 1.1 mol eq of amide 
coupling reagent 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) 
and 2.0 eq of N,N-diisopropylethylamine (DIPEA) were stirred in CH2Cl2 at room temperature with 1.0 
eq of phenylacetic acid to form the activated hydroxybenxzotriazoyl ester in one flask (Flask 1) and 2.0 
mol eq of KH was stirred in THF at 0 °C  with 1.0 eq of aldehyde 5 in a separate flask (Flask 2) to 
generate the K+ pyrrolate salt.  Pre-cooling Flask 1 to 0 °C and pouring its contents into Flask 2 at 0 °C 
in one portion completed the procedure (Scheme 1). 
 
 Employing the method with a systematic series of mono-substituted phenylacetic acid 
derivatives carrying F, Cl, Br, Me, OCH3 and NO2 groups at each of the 2ʹ-, 3ʹ - and 4ʹ -positions 
similarly provided analogues 7-24 (Scheme 1). While the yields were low to moderate (4-48%) the 
simple procedure allowed rapid access to useable quantities of pure analogues for the SAR study. 1H 
and 13C NMR data for all compounds were unambiguous and consistent with 2-aryl-3H-pyrrolizin-3-
ones. A single crystal X-ray structure obtained for 2ʹ-NO2 derivative 22 further confirmed its structure 
(Figure 2). The X-ray structure revealed that the 2ʹ-nitrophenyl ring was tilted 35.5o relative to the 
plane of the 3H-pyrrolizin-3-one ring system and positioned the electron-deficient NO2 nitrogen in 
close proximity to the electronegative carbonyl oxygen (2.8 Å), suggesting a favourable interaction 




































R1 R2 R3 Compound Yield %
H H H 6 48
F H H 7 37




















































































Figure 2. Single crystal X-ray structure (ORTEP) of 22. Anisotropic displacement ellipsoids represent 
30% probability levels. Hydrogen atoms are drawn as circles with small radii. Crystallographic data are 
provided in the Supporting Information. Atomic coordinates, bond lengths and angles and displacement 
parameters have been deposited at the Cambridge Crystallographic Data Centre (CCDC accession 
number 1439414). 
 
 Compounds 6-24 were screened for in vitro angiogenesis inhibitory activity at 10 M using the 
human umbilical vein endothelial cell (HUVEC)-based endothelial tube formation assay.17 Matrix-
cultured HUVECs differentiate in response to growth factors, becoming elongated and motile and able 
to self-organise into capillary-like structures over a 2-12 hour period. This process is disrupted in a 
dose-dependent manner by small molecule inhibitors of angiogenesis.18 Quantification of angiogenesis 
and the inhibitory effects of compounds uses the method of Aranda.17 Briefly, images are captured and 
the cells tallied and categorised as ellipsoid (undifferentiated), sprouting (differentiating) or connected 
to other cells (Supporting Information, Figure S1). Total numbers of closed polyhedra are also counted, 
along with ‘complex meshes’ or polyhedral containing walls more than 2 cells thick. Input of the data 
into an equation (Supporting Information, Equation S1) generates an angiogenesis score, which is then 
expressed as a percentage relative to the angiogenesis score of the vehicle control (100% angiogenesis). 




Figure 3. (a) Inhibition of angiogenesis by 5,7-dimethyl-2-aryl-3H-pyrrolizin-3-ones 6-24 in HUVEC 
endothelial tube formation assay. Angiogenesis scores represent percentages (± SEM) relative to the 
angiogenesis score of the vehicle (DMSO) control (100% angiogenesis). All compounds were present 
at 10 µM. *An additional 1 M data point is shown for the most potent inhibitor 22. (b) Representative 
images showing greater angiogenesis inhibition in the presence of 2ʹ-NO2 analogue 22 (right) relative 
to 2ʹ-fluoro 7 (left, both compounds present at 10 µM). 
 
 Figure 3 (a) shows that 2ʹ-NO2 analogue 22 was the most potent inhibitor in the series, reducing 
angiogenesis to 74.0% ± 12.6 of vehicle at 1 µM and 29.7% ± 4.1 at 10 µM. Sunitinib 1  completely 
inhibited angiogenesis at 10 µM. The 3ʹ-NO2 23 and 4ʹ-NO2 24 analogues showed almost no activity. 
Indeed all 3ʹ (i.e. 8, 11, 14, 17, 20) and 4ʹ (i.e. 9, 12, 15, 18)-substituted compounds failed to show 
notable activity, confirming that these positions do not tolerate substitution. The unsubstituted 
derivative 6 showed modest activity (68.4% ± 6.6 of vehicle) and similar activities were observed with 
the 2ʹ-fluoro 7, 2ʹ-bromo 13, 2ʹ-methyl 16 and 2ʹ-methoxy 19 analogues. 2ʹ-Chloro derivative 10 
showed no activity. Compound 22 was shown to be 4-fold less toxic than sunitinib 1 towards related 
SVEC4-10 murine endothelial cells (Supporting Information, Figure S2), consistent with general 
cytotoxicity not being responsible for the observed anti-angiogenic effects. We conclude that while the 
3ʹ- and 4ʹ-positions are intolerant of substitution, 2ʹ-substituents are tolerated to some extent and in 
some cases (e.g. NO2 group) they can increase activity. This is in agreement with structure-activity 
conclusions from our previous work showing that ortho-nitro groups contribute favourably to anti-




 Compounds 6 and 22 were examined next in a rat aortic ring assay to confirm their anti-
angiogenic properties in a more physiologically relevant context. In this model, 1 mm rings sectioned 
from female rat aortas are suspended in a fibrin gel matrix and exposed to growth media. The aortic 
sections sprout new vessels over 5 days, which are scored manually as the % field of view (FOV) 
occupied (by vessels) under a light microscope (40X).7,19 Inhibitors of angiogenesis produce a 
quantifiable reduction in % FOV occupancy (See Supporting Information for further details). The 
vehicle control (DMSO, no compound) showed 86% FOV occupancy under the assay conditions 
(Figure 4). Two positive control compounds PI-88 and SU5416 2 were included in the study. PI-88 is a 
highly sulfated oligosaccharide-based angiogenesis inhibitor undergoing Phase III clinical trials as a 
treatment following cancer resection in patients with hepatitis virus-related hepatocellular carcinoma.20 
At 100 µg/mL PI-88 reduced % FOV occupancy to 39%. SU5416 2 (synthesised in-house using the 
literature method)21 reduced % FOV occupancy to 61% at 1 µg/mL and 10% at 10 µg/mL. Compound 
22 produced no reduction in % FOV occupancy at 1 µg/mL but showed a marked effect at 10 µg/mL 
(4% FOV occupancy). Compound 6, which showed lower potency than 22 in the endothelial tube 
formation assay, showed reductions in % FOV occupancy only slightly less than 22 at 10 µg/mL 
(Figure 4).  
 
 
Figure 4. Inhibition of angiogenesis by 6 and 22 in rat aortic ring assay. Data for positive controls PI-
88 (100 g/mL) and SU5416 2 and negative control (DMSO vehicle, no compound) are shown for 
comparison. Data represent the mean % FOV occupancy (± SEM) generated from at least six replicate 
cultures of each compound. 
 
 In summary, a divergent one-pot synthesis of 5,7-dimethyl-2-aryl-3H-pyrrolizin-3-ones was 
developed using commercially available mono-substituted phenylacetic acids and pyrrole aldehyde 5. 
Usable quantities of all analogues for the SAR study were obtained but scope remains for improving 
the yields. Nineteen analogues were synthesised and screened for anti-angiogenesis activity in an 
endothelial tube formation assay. The 2ʹ-NO2 analogue 22 was identified as the most potent inhibitor 
and the unsubstituted parent compound 6 and 2ʹ-fluoro 7, 2ʹ-bromo 13, 2ʹ-methyl 16 and 2ʹ-methoxy 19 
derivatives showed activity. In contrast, all 3ʹ- and 4ʹ-substituted analogues were inactive. Compounds 
6 and 22 were advanced to a rat aortic ring angiogenesis assay to corroborate their anti-angiogenic 
properties in a more physiologically relevant context. Both compounds showed robust inhibitory 
effects at 10 g/mL, confirming 5,7-dimethyl-2-aryl-3H-pyrrolizin-3-ones as a new class of 
angiogenesis inhibitors. Further structure-activity studies aimed at identifying more potent inhibitors 
are warranted. Key targets to pursue would include sunitinib-like analogues, where the basic N,N-
diethylethylenediamine side chain amide of sunitinib is appended at the 6-position of 5,7-dimethyl-2-
aryl-3H-pyrrolizin-3-ones. Profiling the class for activity against a panel of RTKs should provide 
insights into the mechanism of action of these compounds. 
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